Since the onset of the COVID-19 pandemic, the healthcare sector has been in the spotlight. Presently, when the worst of the COVID-19 is behind us, healthcare has still restored some long-term attributes such as…
new cost-saving and care-improving advances in medical technologies. Additionally, the sector shows attractive valuation, balance sheets, and stock buybacks.
This year, the healthcare sector has seen an IPO boom. Since healthcare spending is expected to increase significantly this year, many newly listed stocks are expected to witness solid growth.
Healthcare IPOs, 2seventy bio, Inc. (TSVT – Get Rating), Regencell Bioscience Holdings Limited (RGC – Get Rating), and Biofrontera Inc. (BFRI – Get Rating) have generated significant returns since their stock market debut and could be ideal additions to one’s watchlist.
TSVT operates as a cell and gene therapy company that researches, develops, and commercializes cancer treatments in the United States. The company started trading independently on November 5, 2021, separated from bluebird bio, Inc. (BLUE), as a publicly-traded company on the Nasdaq Global Select Market.
On December 1, TSVT announced that the United States Food and Drug Administration (FDA) had accepted the Investigational New Drug (IND) that was developed in collaboration with Seattle Children’s Therapeutics for the potential treatment of acute myeloid leukemia (AML). If commercialized, this new drug could add to the company’s revenues.
For the fiscal third quarter ended September 30, TSVT’s total revenues increased 4.5% year-over-year to $19.26 million. For the nine months ended September 30, net cash provided by financing activities rose 475.5% from the same period last year to $168.20 million.
The consensus EPS estimate for the next year (fiscal 2022) indicates a 5.5% year-over-year increase. Likewise, the consensus revenue estimate of $104.36 million for the upcoming year reflects an improvement of 94% from the current year.
The stock has gained 8.3% over the past month to close Thursday’s trading session at $31.01. It has gained 2.9% intra-day.
RGC is a Traditional Chinese Medicine (TCM) biosciences company headquartered in Causeway Bay, Hong Kong. The company researches, develops, and commercializes TCM to treat degeneration and neuro-cognitive disorders.
RGC went public on the Nasdaq Capital Market on July 16, 2021, in a traditional IPO process. The company received $21.9 million gross proceeds from the offering, which is expected to be used to fund the second research study, the company’s TCM formulae and products, and general corporate purposes. On July 20…
Continue reading at STOCKNEWS.com